Pegstim 6mg Injection PFS

About

Pegstim 6mg Injection PFS contains Pegfilgrastim, a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). This medication works by stimulating the production, maturation, and release of neutrophils from the bone marrow. Neutrophils are a type of white blood cell crucial for fighting bacterial infections. Pegfilgrastim is designed to reduce the incidence of febrile neutropenia, a serious complication characterized by fever and a dangerously low neutrophil count, which often occurs in cancer patients undergoing myelosuppressive chemotherapy. The pegylation process extends the half-life of G-CSF, allowing for a single dose per chemotherapy cycle, thereby simplifying administration and improving patient convenience compared to daily G-CSF injections.

Uses

• Prevention of febrile neutropenia in cancer patients
• Reduction of infection risk during chemotherapy
• Stimulation of neutrophil production
• Management of chemotherapy-induced myelosuppression

Directions For Use

Administered subcutaneously, typically once per chemotherapy cycle, at least 24 hours after chemotherapy.

Benefits

• Significantly reduces incidence of febrile neutropenia.
• Decreases risk of infection during chemotherapy.
• Allows for on-schedule chemotherapy cycles.
• Convenient single dose per cycle.
• Improves patient quality of life.
• Supports bone marrow recovery.

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Headache
• Fatigue
• Nausea
• Injection site reactions
• Splenomegaly (enlarged spleen)
• Thrombocytopenia
• Leukocytosis
• Allergic reactions
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may worsen general fatigue or body aches.
• Pregnancy - Use only if clearly needed; animal studies show some risk, but human data are limited. Discuss risks with a doctor.
• Breastfeeding - Unknown if excreted in human milk; caution advised. Consult a healthcare provider.
• Liver - No specific dose adjustment required for liver impairment.
• Kidney - No specific dose adjustment required for renal impairment.
• Lung - Rarely, serious pulmonary adverse reactions, including interstitial pneumonia, can occur; monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.